TN2014000357A1 - Heterocyclyl compounds - Google Patents

Heterocyclyl compounds

Info

Publication number: TN2014000357A1
Authority: TN; Tunisia
Prior art keywords: compounds; formula; present; heterocyclyl compounds; heteroaryl
Prior art date: 2012-03-14

Application number

TNP2014000357A

Other languages

English (en)

Inventor

Venkata P Palle

Rajender Kumar Kamboj

Bhavesh Dave

Rakesh Kumar Banerjee

Samiron Phukan

Abhijit Datta Khoje

Rajkumar Hangarge

Jitendra Sambhaji Jadhav

Original Assignee

Lupin Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2012-03-14

Filing date

2014-08-18

Publication date

2015-12-21

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997632&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2014000357(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2014-08-18 Application filed by Lupin Ltd filed Critical Lupin Ltd

2015-12-21 Publication of TN2014000357A1 publication Critical patent/TN2014000357A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Immunology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Physical Education & Sports Medicine (AREA)
Hematology (AREA)
Rheumatology (AREA)
Heart & Thoracic Surgery (AREA)
Radiology & Medical Imaging (AREA)
Pathology (AREA)
Urology & Nephrology (AREA)
Obesity (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Orthopedic Medicine & Surgery (AREA)
Dermatology (AREA)
Transplantation (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)

TNP2014000357A 2012-03-14 2014-08-18 Heterocyclyl compounds TN2014000357A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
IN288KO2012		2012-03-14
PCT/IB2013/051915 WO2013136254A1 (fr)	2012-03-14	2013-03-11	Composés hétérocyclyle

Publications (1)

Publication Number	Publication Date
TN2014000357A1 true TN2014000357A1 (en)	2015-12-21

Family

ID=47997632

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
TNP2014000356A TN2014000356A1 (en)	2012-03-14	2014-08-18	Heterocyclyl compounds as mek inhibitors
TNP2014000357A TN2014000357A1 (en)	2012-03-14	2014-08-18	Heterocyclyl compounds

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
TNP2014000356A TN2014000356A1 (en)	2012-03-14	2014-08-18	Heterocyclyl compounds as mek inhibitors

Country Status (36)

Country	Link
US (5)	US9428499B2 (fr)
EP (2)	EP2834236B1 (fr)
JP (3)	JP6431770B2 (fr)
KR (4)	KR20140138910A (fr)
CN (4)	CN104271577A (fr)
AP (2)	AP3859A (fr)
AU (4)	AU2013234009B2 (fr)
BR (1)	BR112014022713B1 (fr)
CA (2)	CA2865164C (fr)
CL (2)	CL2014002412A1 (fr)
CO (2)	CO7160029A2 (fr)
CR (2)	CR20140463A (fr)
CU (2)	CU24335B1 (fr)
DK (2)	DK2834236T3 (fr)
DO (2)	DOP2014000203A (fr)
EA (2)	EA028232B1 (fr)
ES (2)	ES2741896T3 (fr)
GE (2)	GEP201706774B (fr)
GT (2)	GT201400195A (fr)
HK (2)	HK1202538A1 (fr)
IL (2)	IL234560A (fr)
IN (2)	IN2014MN01754A (fr)
MA (2)	MA37405A1 (fr)
MX (3)	MX366426B (fr)
MY (2)	MY175950A (fr)
NI (2)	NI201400108A (fr)
NZ (2)	NZ629442A (fr)
PE (2)	PE20141974A1 (fr)
PH (2)	PH12014502041A1 (fr)
PL (1)	PL2834237T3 (fr)
SG (2)	SG11201405007QA (fr)
TN (2)	TN2014000356A1 (fr)
TR (1)	TR201811976T4 (fr)
UA (2)	UA114906C2 (fr)
WO (2)	WO2013136254A1 (fr)
ZA (1)	ZA201406186B (fr)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US8754114B2 (en)	2010-12-22	2014-06-17	Incyte Corporation	Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
CN104271577A (zh)	2012-03-14	2015-01-07	鲁宾有限公司	作为mek抑制剂的杂环基化合物
LT3495367T (lt)	2012-06-13	2021-02-25	Incyte Holdings Corporation	Pakeistieji tricikliniai junginiai, kaip fgfr inhibitoriai
US9388185B2 (en)	2012-08-10	2016-07-12	Incyte Holdings Corporation	Substituted pyrrolo[2,3-b]pyrazines as FGFR inhibitors
US9266892B2 (en)	2012-12-19	2016-02-23	Incyte Holdings Corporation	Fused pyrazoles as FGFR inhibitors
SI2986610T1 (en)	2013-04-19	2018-04-30	Incyte Holdings Corporation	Bicyclic heterocycles as inhibitors of FGFR
PT3061747T (pt) *	2013-10-25	2021-05-04	Shanghai hengrui pharmaceutical co ltd	Derivados pirídicos de cetona, método para preparar os mesmos e aplicação farmacêutica dos mesmos
WO2016009306A1 (fr) *	2014-07-15	2016-01-21	Lupin Limited	Composés hétérocyclyles utilisés comme inhibiteurs de mek
WO2016035008A1 (fr) *	2014-09-04	2016-03-10	Lupin Limited	Dérivés de pyridopyrimidine utilisés comme inhibiteurs de mek
US10851105B2 (en)	2014-10-22	2020-12-01	Incyte Corporation	Bicyclic heterocycles as FGFR4 inhibitors
MA41551A (fr)	2015-02-20	2017-12-26	Incyte Corp	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
WO2016134294A1 (fr)	2015-02-20	2016-08-25	Incyte Corporation	Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
SG10201913036RA (en)	2015-02-20	2020-02-27	Incyte Corp	Bicyclic heterocycles as fgfr inhibitors
WO2018115380A1 (fr)	2016-12-22	2018-06-28	Boehringer Ingelheim International Gmbh	Nouvelles quinazolines à substitution benzylamino et leurs dérivés en tant qu'inhibiteurs de sos1
AR111960A1 (es)	2017-05-26	2019-09-04	Incyte Corp	Formas cristalinas de un inhibidor de fgfr y procesos para su preparación
PL3728254T3 (pl) *	2017-12-21	2023-06-12	Boehringer Ingelheim International Gmbh	Benzyloaminopodstawione pirydopirymidynony i pochodne jako inhibitory sos1
WO2019213544A2 (fr)	2018-05-04	2019-11-07	Incyte Corporation	Formes solides d'un inhibiteur de fgfr et leurs procédés de préparation
EP3788046A1 (fr)	2018-05-04	2021-03-10	Incyte Corporation	Sels d'un inhibiteur de fgfr
US11628162B2 (en)	2019-03-08	2023-04-18	Incyte Corporation	Methods of treating cancer with an FGFR inhibitor
AU2020242287A1 (en)	2019-03-21	2021-09-02	INSERM (Institut National de la Santé et de la Recherche Médicale)	A Dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2022537044A (ja)	2019-06-19	2022-08-23	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	抗がん併用療法
US11591329B2 (en)	2019-07-09	2023-02-28	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021018866A1 (fr) *	2019-07-30	2021-02-04	Edvince Ab	Inhibiteur de mek pour le traitement d'un accident vasculaire cérébral
EP3797899A1 (fr)	2019-09-27	2021-03-31	Primetals Technologies Austria GmbH	Dispositif et procédé de détection d'un mouvement d'un corps dans une installation industrielle
US12122767B2 (en)	2019-10-01	2024-10-22	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
JP2022552324A (ja)	2019-10-14	2022-12-15	インサイト・コーポレイション	Ｆｇｆｒ阻害剤としての二環式複素環
WO2021076728A1 (fr)	2019-10-16	2021-04-22	Incyte Corporation	Hétérocycles bicycliques en tant qu'inhibiteurs de fgfr
WO2021089791A1 (fr)	2019-11-08	2021-05-14	INSERM (Institut National de la Santé et de la Recherche Médicale)	Méthodes pour le traitement de cancers qui ont acquis une résistance aux inhibiteurs de kinase
CN115151539A (zh)	2019-12-04	2022-10-04	因赛特公司	Fgfr抑制剂的衍生物
US11897891B2 (en)	2019-12-04	2024-02-13	Incyte Corporation	Tricyclic heterocycles as FGFR inhibitors
US12012409B2 (en)	2020-01-15	2024-06-18	Incyte Corporation	Bicyclic heterocycles as FGFR inhibitors
WO2021148581A1 (fr)	2020-01-22	2021-07-29	Onxeo	Nouvelle molécule dbait et son utilisation
US20230212164A1 (en)	2020-06-02	2023-07-06	Boehringer Ingelheim International Gmbh	Annulated 2-amino-3-cyano thiophenes and derivatives for the treatment of cancer
TWI825637B (zh)	2021-03-31	2023-12-11	美商輝瑞股份有限公司	啶－１，６（２ｈ，７ｈ）－二酮
CN117479942A (zh)	2021-04-09	2024-01-30	勃林格殷格翰国际有限公司	抗癌疗法
CA3215903A1 (fr)	2021-04-12	2022-10-20	Incyte Corporation	Polytherapie comprenant un inhibiteur de fgfr et un agent de ciblage de nectine-4
EP4323066A1 (fr) *	2021-04-16	2024-02-21	Ikena Oncology, Inc.	Inhibiteurs de mek et leurs utilisations
CA3220274A1 (fr)	2021-06-09	2022-12-15	Incyte Corporation	Heterocycles tricycliques en tant qu'inhibiteurs de fgfr
EP4441050A1 (fr)	2021-12-01	2024-10-09	Boehringer Ingelheim International GmbH	2-amino-3-cyano thiophènes annelés et leurs dérivés pour le traitement du cancer
TW202337432A (zh)	2021-12-01	2023-10-01	德商百靈佳殷格翰國際股份有限公司	用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
TW202337431A (zh)	2021-12-01	2023-10-01	德商百靈佳殷格翰國際股份有限公司	用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
EP4441051A1 (fr)	2021-12-01	2024-10-09	Boehringer Ingelheim International GmbH	Composés de dégradation de kras comprenant des 2-amino-3-cyano thiophènes annelés
TW202340208A (zh)	2021-12-01	2023-10-16	德商百靈佳殷格翰國際股份有限公司	用於治療癌症之環狀2-胺基-3-氰基噻吩及衍生物
CN114573581B (zh) *	2022-03-30	2023-09-01	沈阳药科大学	5-取代氨基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114456166B (zh) *	2022-03-30	2023-06-16	沈阳药科大学	5-取代氨基-3-甲基吡啶并[2,3-d]嘧啶类化合物及其制备与应用
CN114605408B (zh) *	2022-03-30	2023-06-16	沈阳药科大学	5-羟基-1,3-二取代苯基吡啶并[2,3-d]嘧啶类化合物及其制法和应用
CN114573582B (zh) *	2022-03-30	2023-06-16	沈阳药科大学	1,2,3,4-四氢吡啶并[2,3-d]嘧啶类化合物及其制备方法和应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en)	1983-01-06	1985-02-26	Technology Unlimited, Inc.	Masking of liposomes from RES recognition
US5019369A (en)	1984-10-22	1991-05-28	Vestar, Inc.	Method of targeting tumors in humans
US4837028A (en)	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
UA72612C2 (en) *	2000-07-06	2005-03-15		Pyrido[2.3-d]pyrimidine and pyrimido[4.5-d]pyrimidine nucleoside analogues, prodrugs and method for inhibiting growth of neoplastic cells
US6825180B2 (en) *	2001-05-18	2004-11-30	Cell Therapeutics, Inc.	Pyridopyrimidine compounds and their uses
GB0129099D0 (en)	2001-12-05	2002-01-23	Astrazeneca Ab	Chemical compounds
KR20060111716A (ko) *	2002-01-22	2006-10-27	워너-램버트 캄파니 엘엘씨	2-(피리딘-2-일아미노)-피리도[2,3-ｄ]피리미딘-7-온
US7235537B2 (en)	2002-03-13	2007-06-26	Array Biopharma, Inc.	N3 alkylated benzimidazole derivatives as MEK inhibitors
WO2005051302A2 (fr)	2003-11-19	2005-06-09	Array Biopharma Inc.	Inhibiteurs bicycliques de mek, et leurs procedes d'utilisation
US7378423B2 (en) *	2004-06-11	2008-05-27	Japan Tobacco Inc.	Pyrimidine compound and medical use thereof
ATE383360T1 (de) *	2004-06-11	2008-01-15	Japan Tobacco Inc	5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2h- pyrido(2,3-d)pyrimidinderivate und verwandte verbindungen zur behandlung von krebs
AU2009344690A1 (en)	2009-04-21	2011-10-27	Novartis Ag	Heterocyclic compounds as MEK inhibitors
CN104271577A (zh)	2012-03-14	2015-01-07	鲁宾有限公司	作为mek抑制剂的杂环基化合物

2013
- 2013-03-11 CN CN201380023296.2A patent/CN104271577A/zh active Pending
- 2013-03-11 UA UAA201411011A patent/UA114906C2/uk unknown
- 2013-03-11 CU CUP2014000109A patent/CU24335B1/es unknown
- 2013-03-11 ES ES13711973T patent/ES2741896T3/es active Active
- 2013-03-11 CN CN201710823363.9A patent/CN107698585A/zh active Pending
- 2013-03-11 WO PCT/IB2013/051915 patent/WO2013136254A1/fr active Application Filing
- 2013-03-11 PL PL13712929T patent/PL2834237T3/pl unknown
- 2013-03-11 IN IN1754MUN2014 patent/IN2014MN01754A/en unknown
- 2013-03-11 GE GEAP201313596A patent/GEP201706774B/en unknown
- 2013-03-11 SG SG11201405007QA patent/SG11201405007QA/en unknown
- 2013-03-11 AU AU2013234009A patent/AU2013234009B2/en active Active
- 2013-03-11 NZ NZ629442A patent/NZ629442A/en not_active IP Right Cessation
- 2013-03-11 MA MA37405A patent/MA37405A1/fr unknown
- 2013-03-11 MA MA37400A patent/MA37400B1/fr unknown
- 2013-03-11 NZ NZ629432A patent/NZ629432A/en unknown
- 2013-03-11 EA EA201491672A patent/EA028232B1/ru unknown
- 2013-03-11 US US14/385,092 patent/US9428499B2/en active Active
- 2013-03-11 JP JP2014561564A patent/JP6431770B2/ja active Active
- 2013-03-11 IN IN1755MUN2014 patent/IN2014MN01755A/en unknown
- 2013-03-11 CU CUP2014000110A patent/CU24272B1/xx unknown
- 2013-03-11 MX MX2018003665A patent/MX366426B/es unknown
- 2013-03-11 KR KR1020147028556A patent/KR20140138910A/ko active Application Filing
- 2013-03-11 DK DK13711973.1T patent/DK2834236T3/da active
- 2013-03-11 KR KR1020197024543A patent/KR102241111B1/ko active IP Right Grant
- 2013-03-11 EP EP13711973.1A patent/EP2834236B1/fr active Active
- 2013-03-11 MX MX2014010928A patent/MX355474B/es active IP Right Grant
- 2013-03-11 MY MYPI2014002638A patent/MY175950A/en unknown
- 2013-03-11 US US14/385,106 patent/US9573944B2/en active Active
- 2013-03-11 PE PE2014001400A patent/PE20141974A1/es active IP Right Grant
- 2013-03-11 EP EP13712929.2A patent/EP2834237B1/fr active Active
- 2013-03-11 EA EA201491671A patent/EA029768B1/ru unknown
- 2013-03-11 CA CA2865164A patent/CA2865164C/fr active Active
- 2013-03-11 KR KR1020147028557A patent/KR20140138911A/ko not_active IP Right Cessation
- 2013-03-11 DK DK13712929.2T patent/DK2834237T3/en active
- 2013-03-11 PE PE2014001399A patent/PE20141973A1/es active IP Right Grant
- 2013-03-11 UA UAA201411014A patent/UA114907C2/uk unknown
- 2013-03-11 ES ES13712929T patent/ES2684517T3/es active Active
- 2013-03-11 WO PCT/IB2013/051908 patent/WO2013136249A1/fr active Application Filing
- 2013-03-11 MX MX2014010925A patent/MX355526B/es active IP Right Grant
- 2013-03-11 TR TR2018/11976T patent/TR201811976T4/tr unknown
- 2013-03-11 SG SG11201405006PA patent/SG11201405006PA/en unknown
- 2013-03-11 CN CN201810086896.8A patent/CN108383836B/zh active Active
- 2013-03-11 AP AP2014008009A patent/AP3859A/en active
- 2013-03-11 AU AU2013234014A patent/AU2013234014B2/en not_active Ceased
- 2013-03-11 KR KR1020197017334A patent/KR102240101B1/ko active IP Right Grant
- 2013-03-11 CA CA2865167A patent/CA2865167C/fr not_active Expired - Fee Related
- 2013-03-11 GE GEAP201313595A patent/GEP201706671B/en unknown
- 2013-03-11 MY MYPI2014002639A patent/MY174188A/en unknown
- 2013-03-11 AP AP2014008008A patent/AP3834A/en active
- 2013-03-11 BR BR112014022713-6A patent/BR112014022713B1/pt active IP Right Grant
- 2013-03-11 JP JP2014561567A patent/JP6093384B2/ja active Active
- 2013-03-11 CN CN201380014210.XA patent/CN104203947A/zh active Pending
2014
- 2014-08-18 TN TNP2014000356A patent/TN2014000356A1/fr unknown
- 2014-08-18 TN TNP2014000357A patent/TN2014000357A1/fr unknown
- 2014-08-22 ZA ZA2014/06186A patent/ZA201406186B/en unknown
- 2014-09-09 IL IL234560A patent/IL234560A/en active IP Right Grant
- 2014-09-09 IL IL234559A patent/IL234559A/en active IP Right Grant
- 2014-09-10 DO DO2014000203A patent/DOP2014000203A/es unknown
- 2014-09-10 DO DO2014000204A patent/DOP2014000204A/es unknown
- 2014-09-11 NI NI201400108A patent/NI201400108A/es unknown
- 2014-09-11 NI NI201400107A patent/NI201400107A/es unknown
- 2014-09-12 CL CL2014002412A patent/CL2014002412A1/es unknown
- 2014-09-12 CL CL2014002411A patent/CL2014002411A1/es unknown
- 2014-09-12 GT GT201400195A patent/GT201400195A/es unknown
- 2014-09-12 PH PH12014502041A patent/PH12014502041A1/en unknown
- 2014-09-12 GT GT201400196A patent/GT201400196A/es unknown
- 2014-09-12 PH PH12014502040A patent/PH12014502040B1/en unknown
- 2014-10-06 CO CO14221195A patent/CO7160029A2/es unknown
- 2014-10-06 CR CR20140463A patent/CR20140463A/es unknown
- 2014-10-06 CR CR20140464A patent/CR20140464A/es unknown
- 2014-10-06 CO CO14221191A patent/CO7170131A2/es unknown
2015
- 2015-03-25 HK HK15103051.3A patent/HK1202538A1/xx unknown
- 2015-07-09 HK HK15106571.7A patent/HK1206020A1/xx not_active IP Right Cessation
2016
- 2016-07-25 US US15/218,980 patent/US9555035B2/en active Active
- 2016-12-22 US US15/388,327 patent/US9969731B2/en active Active
2017
- 2017-01-06 US US15/400,627 patent/US9827247B2/en active Active
- 2017-01-25 AU AU2017200493A patent/AU2017200493B2/en active Active
2018
- 2018-04-12 AU AU2018202568A patent/AU2018202568B2/en active Active
- 2018-05-01 JP JP2018088389A patent/JP6630771B2/ja active Active

Also Published As

Publication number	Publication date
UA114906C2 (uk)	2017-08-28
MY174188A (en)	2020-03-12
HK1206020A1 (en)	2015-12-31
PH12014502041B1 (en)	2014-11-24
MA37400B1 (fr)	2019-11-29
SG11201405007QA (en)	2014-10-30
CL2014002411A1 (es)	2015-04-06
AU2013234009A1 (en)	2014-09-25
JP6431770B2 (ja)	2018-11-28
CA2865164A1 (fr)	2013-09-19
NZ629432A (en)	2017-01-27
CU20140110A7 (es)	2014-11-27
CA2865167C (fr)	2019-08-06
CA2865167A1 (fr)	2013-09-19
SG11201405006PA (en)	2014-10-30
NZ629442A (en)	2016-12-23
AU2013234009B2 (en)	2016-10-27
ZA201406186B (en)	2016-06-29
MA37405A1 (fr)	2016-03-31
JP2018115215A (ja)	2018-07-26
KR20190100472A (ko)	2019-08-28
IN2014MN01755A (fr)	2015-07-03
CN108383836B (zh)	2021-11-12
MX355474B (es)	2018-04-16
PH12014502041A1 (en)	2014-11-24
CN104271577A (zh)	2015-01-07
EP2834237B1 (fr)	2018-06-06
BR112014022713B1 (pt)	2021-09-08
AU2013234014B2 (en)	2017-02-02
GEP201706774B (en)	2017-11-27
AP3834A (en)	2016-09-30
CR20140464A (es)	2014-11-28
MA37400A1 (fr)	2016-05-31
CU24335B1 (es)	2018-04-03
AP2014008008A0 (en)	2014-10-31
US9573944B2 (en)	2017-02-21
PE20141973A1 (es)	2014-12-12
JP6093384B2 (ja)	2017-03-08
IL234560A (en)	2017-06-29
CL2014002412A1 (es)	2015-03-06
PH12014502040A1 (en)	2014-11-24
AU2018202568A1 (en)	2018-05-10
CU20140109A7 (es)	2014-11-27
EP2834236B1 (fr)	2019-05-22
DK2834236T3 (da)	2019-08-26
PH12014502040B1 (en)	2014-11-24
KR20190073597A (ko)	2019-06-26
KR102240101B1 (ko)	2021-04-14
PE20141974A1 (es)	2014-12-12
US9827247B2 (en)	2017-11-28
BR112014022713A2 (fr)	2017-06-20
AU2017200493A1 (en)	2017-02-16
US20160331753A1 (en)	2016-11-17
TR201811976T4 (tr)	2018-09-21
GT201400196A (es)	2017-09-28
CO7160029A2 (es)	2015-01-15
EA201491672A1 (ru)	2014-12-30
JP2015514056A (ja)	2015-05-18
US9969731B2 (en)	2018-05-15
US9555035B2 (en)	2017-01-31
IN2014MN01754A (fr)	2015-07-03
MX2014010928A (es)	2015-04-10
AU2018202568B2 (en)	2019-05-09
GT201400195A (es)	2017-11-09
MX366426B (es)	2019-07-08
EA028232B1 (ru)	2017-10-31
DOP2014000203A (es)	2015-02-15
NI201400107A (es)	2014-11-26
US20170112840A1 (en)	2017-04-27
US20170101408A1 (en)	2017-04-13
NI201400108A (es)	2014-11-28
KR20140138910A (ko)	2014-12-04
AU2017200493B2 (en)	2018-03-29
MX355526B (es)	2018-04-20
CA2865164C (fr)	2021-06-08
US20150133424A1 (en)	2015-05-14
IL234559A (en)	2017-06-29
ES2684517T3 (es)	2018-10-03
US9428499B2 (en)	2016-08-30
WO2013136249A1 (fr)	2013-09-19
CU24272B1 (es)	2017-08-08
CN108383836A (zh)	2018-08-10
AP3859A (en)	2016-10-31
KR102241111B1 (ko)	2021-04-15
AU2013234014A1 (en)	2014-09-25
EA029768B1 (ru)	2018-05-31
CR20140463A (es)	2014-11-28
HK1202538A1 (en)	2015-10-02
US20150299186A1 (en)	2015-10-22
MY175950A (en)	2020-07-16
TN2014000356A1 (en)	2015-12-21
PL2834237T3 (pl)	2018-11-30
CO7170131A2 (es)	2015-01-28
JP6630771B2 (ja)	2020-01-15
DOP2014000204A (es)	2015-02-15
CN107698585A (zh)	2018-02-16
GEP201706671B (en)	2017-05-25
JP2015509975A (ja)	2015-04-02
EP2834237A1 (fr)	2015-02-11
KR20140138911A (ko)	2014-12-04
DK2834237T3 (en)	2018-08-27
WO2013136254A1 (fr)	2013-09-19
AP2014008009A0 (en)	2014-10-31
EP2834236A1 (fr)	2015-02-11
ES2741896T3 (es)	2020-02-12
CN104203947A (zh)	2014-12-10
MX2014010925A (es)	2015-04-10
EA201491671A1 (ru)	2014-12-30
UA114907C2 (uk)	2017-08-28

Publication	Publication Date	Title
PH12014502040A1 (en)	2014-11-24	Heterocyclyl compounds
UA109010C2 (en)	2015-07-10	MORPHOLINOPYRIMIDINES AND THEIR APPLICATIONS IN THERAPY
PH12014502605A1 (en)	2015-02-02	Uracyl spirooxetane nucleosides
MY175854A (en)	2020-07-14	Novel quinolone derivatives
PH12014502524A1 (en)	2015-01-12	Carboxylic acid compounds
MD20140063A2 (ro)	2014-12-31	Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
IN2015DN01156A (fr)	2015-06-26
IN2014MN02598A (fr)	2015-07-24
PH12014501514A1 (en)	2014-10-08	New azetidine derivatives, pharmaceutical compositions and uses thereof
IN2015DN01119A (fr)	2015-06-26
JO3115B1 (ar)	2017-09-20	مركبات بيريدازينون واستخدامها كمثبطات daao
EA201390984A1 (ru)	2014-04-30	Гетероциклические соединения, подходящие для лечения дислипидемии
MX2016006337A (es)	2016-09-06	Compuestos heterociclicos novedosos.
MX2016003522A (es)	2016-12-15	Derivados de quinazolinas y su uso como inhibidores de la adn metiltransferasa.
PH12014501943A1 (en)	2014-11-24	Novel compounds for the treatment of dyslipidemia and related diseases
IN2015DN02109A (fr)	2015-08-14
MY166057A (en)	2018-05-22	Carbocyclic nucleosides and their pharmaceutical use and compositions
TN2014000077A1 (en)	2015-07-01	Pyridazinone compounds and their use as daao inhibitors